Scorpius Holdings, Inc. Announces Pricing of Public Offering
DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated...
DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated...
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data...
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to...
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II...
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
London, United Kingdom--(Newsfile Corp. - May 13, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), today announced a...
DEA FACES FOUR FEDERAL DISTRICT COURT SUITS CLAIMING DISARRAY and CONSTITUTIONAL VIOLATIONS WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024...
BIRMINGHAM, Ala. & CHEYENNE, Wyo.--(BUSINESS WIRE)--As a commitment to the safety and well-being of its inmates, the Wyoming Department of...
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...
Partnership to enable cancer care centers to improve access and efficiency of clinical studies and researchNEW YORK--(BUSINESS WIRE)--Flatiron Health, a...
UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP)...
COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc...
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in...
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)...
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327...
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected...
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed...